FGF21 and metabolic dysfunction-associated steatohepatitis: FGF21 was also recently proven to be an independent predictor and marker of NAFLD in humans [39], and its pharmacological administration has been proposed as an effective treatment to Non-alcoholic steatohepatitis NASH [23].